Company Description
Jasper Therapeutics, Inc., a clinical-stage biotechnology company, develops therapeutic agents for hematopoietic stem cell transplantation and gene therapies.
The company's lead product candidate is briquilimab, which is in clinical development as a novel therapeutic antibody that clears hematopoietic stem cells from bone marrow in patients prior to undergoing allogeneic stem cell therapy or stem cell gene therapy.
It focuses on the development and commercialization of therapeutic agents for diseases, such as chronic spontaneous urticaria, lower to intermediate risk myelodysplastic syndrome, and conditioning regimens for stem cell transplantation.
In addition, it is also developing stem cell transplants for rare diseases such as sickle cell disease, fanconi anemia, chronic granulomatous diseases, and GATA2 MDS, and severe combined immunodeficiency.
Jasper Therapeutics, Inc. is headquartered in Redwood City, California.
| Country | United States |
| Founded | 2018 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 45 |
| CEO | Ronald A. Martell |
Contact Details
Address: 2200 Bridge Pkwy Suite #102 Redwood City, California 94065 United States | |
| Phone | (650) 549-1400 |
| Website | jaspertherapeutics.com |
Stock Details
| Ticker Symbol | JSPR |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001788028 |
| CUSIP Number | 471871103 |
| ISIN Number | US4718712023 |
| Employer ID | 84-2984849 |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Ronald A. Martell | President, Chief Executive Officer and Director |
| Dr. Judith Anne Shizuru M.D., Ph.D. | Co-Founder, Chair of Scientific Advisory Board and Director |
| Jeetinder Singh Mahal M.B.A. | Chief Operating Officer |
| Herbert C. Cross | Chief Financial Officer and Corporate Secretary |
| Dr. Luca Di Noto Ph.D. | Senior Vice President of Technical Operations |
| David Ku M.D. | Vice President of Corporate Development, Portfolio Strategy and Management |
| Matthew Ford | Vice President of Human Resources |
| Dr. Wendy Pang M.D., Ph.D. | Senior Vice President of Research and Translational Medicine |
| Dr. Edwin Jonathan Tucker M.D. | Chief Medical Officer |
| Patricia Carlos | Senior Vice President of Regulatory Affairs and Quality |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Mar 27, 2024 | SC 13G | Statement of acquisition of beneficial ownership by individuals |
| Mar 12, 2024 | 144 | Filing |
| Mar 6, 2024 | 144 | Filing |
| Mar 5, 2024 | S-8 | Securities to be offered to employees in employee benefit plans |
| Mar 5, 2024 | 10-K | Annual Report |
| Mar 4, 2024 | 8-K | Current Report |
| Feb 14, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
| Feb 14, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
| Feb 14, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
| Feb 12, 2024 | SC 13D/A | [Amend] General statement of acquisition of beneficial ownership |